BlackRock reports 1.3% stake in MaxCyte shares
BlackRock, Inc. reports its institutional ownership position in MaxCyte, Inc. common stock.
Rhea-AI Filing Summary
BlackRock, Inc. reports its institutional ownership position in MaxCyte, Inc. common stock. As of June 30, 2026, BlackRock beneficially owned 1,402,591 shares of MaxCyte common stock, representing 1.3% of the outstanding class. BlackRock has sole voting power and sole dispositive power over all 1,402,591 shares, with no shared voting or dispositive power.
The filing notes that various underlying clients have the right to receive dividends or sale proceeds from these shares, but no single person has an interest in more than five percent of MaxCyte’s total outstanding common shares. This amendment reflects BlackRock’s status as a holder of 5 percent or less of the class.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
beneficially owned financial
sole voting power financial
sole dispositive power financial
Schedule 13G regulatory
Power of Attorney regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of MaxCyte (MXCT) does BlackRock currently own?
What class of MaxCyte (MXCT) securities is reported in BlackRock’s 13G/A?
AI-generated analysis. How Rhea-AI works. Not financial advice.